Arbutus Biopharma
ABUS
ABUS
48 hedge funds and large institutions have $26.5M invested in Arbutus Biopharma in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
50% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 18
61% less capital invested
Capital invested by funds: $67.4M → $26.5M (-$40.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
48
Holding in Top 10
–
Calls
$749K
Puts
$13K
Top Buyers
| 1 | +$3.44M | |
| 2 | +$2.45M | |
| 3 | +$1.87M | |
| 4 |
RI
RTW Investments
New York
|
+$1.21M |
| 5 |
HP
Hound Partners
New York
|
+$580K |
Top Sellers
| 1 | -$10.3M | |
| 2 | -$5.27M | |
| 3 | -$2.61M | |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.03M |
| 5 |
Bank of New York Mellon
New York
|
-$713K |